Results 71 to 80 of about 31,387 (227)

Comprehensive analysis and functional validation of key genes in bladder cancer progression

VIEW, EarlyView.
Bladder cancer is highly diverse between patients, making it difficult to accurately predict who will have aggressive disease and poor outcomes. In this study, we integrated single‐cell RNA sequencing with clinical survival data to identify a simple three‐gene signature (FAM3B, C10orf99, and VMP1) that stratifies patients into high‐ and low‐risk groups.
Xiaoning Cheng, Hongxia Zhao, Qian Li, Boyang Liu, Maoping Cai, Xinyi Wang, Jiancong Lie, Yuanyuan Qu, Jianwei Li, Chunlong Yang   +9 more
wiley   +1 more source

The Changing Treatment Landscape for Metastatic Urothelial Carcinoma [PDF]

Journal of the National Comprehensive Cancer Network, 2018
Urothelial carcinoma is the predominant histologic type of bladder cancer. After 30 years of minimal progress in the treatment of advanced-stage disease, recent advances in the genomic characterization of urothelial cancer and breakthroughs in bladder cancer therapeutics have rejuvenated the field.
openaire   +2 more sources

Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Stage IV Melanoma Receiving Immune Checkpoint Inhibitors: A Single‐Center Retrospective Study

The Journal of Dermatology, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for malignant melanoma (MM). However, given variable response rates and potential toxicities, identifying robust biomarkers is crucial. We investigated whether the modified Glasgow Prognostic Score (mGPS) predicts treatment efficacy and toxicity in Asian patients with
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara   +4 more
wiley   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Conditional Survival in de novo Metastatic Urothelial Carcinoma

PLOS ONE, 2015
Second-line therapy is frequently utilized for metastatic urothelial carcinoma, but there are limited data to guide this approach. While an assessment of overall survival based on registry data may not capture the impact of second- and third-line therapies on clinical outcome, this may be reflected in relative conditional survival (RCS).Patients with ...
Sumanta Kumar Pal, Yulan Ingrid Lin, Bertram Yuh, Kara DeWalt, Austin Kazarian, Nicholas Vogelzang, Rebecca A Nelson   +6 more
openaire   +4 more sources

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Survival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis

Bladder Cancer, 2017
Background: Cisplatin-based combination chemotherapy is standard treatment for metastatic urothelial carcinoma; however, the vast majority of patients experience disease progression.
Vaibhav Patel, Ana Collazo Lorduy, Aaron Stern, Omar Fahmy, Rachel Pinotti, Matthew D. Galsky, Georgios Gakis   +6 more
doaj   +1 more source

KRAB Zinc‐Finger Protein ZNF205 Promotes Hepatocellular Carcinoma via p53 Pathway Repression

Cancer Science, EarlyView.
ZNF205 functions as a critical oncogenic regulator in hepatocellular carcinoma (HCC), where it interacts with p53 and functionally suppresses its transcriptional activity by competitively inhibiting p53 binding to target gene promoters. This p53 inactivation mechanism critically contributes to tumor progression in HCC. ABSTRACT The tumor suppressor p53
Xiaofen Huang, Yingchuan Yang, Yuan Ma, Wei Hao, Jingzhuo Jin, Yue Ding, Yiming Zhang, Xiuyuan Zhang, Xinli Li, Qin Song, Jiaqi Liu, Bingxin Liu, Yuanjun Zhai, Chunling Zhao, Jin Wu, Chunyan Tian   +15 more
wiley   +1 more source

Metastatic Bladder Urothelial Carcinoma Masquerading as Myositis

Journal of Medical Cases
Skeletal muscle metastases are uncommon, and metastases of urothelial carcinoma to the skeletal muscle are particularly rare. The most common presentation of skeletal muscle metastases is a focal mass, but their clinical and radiographic findings can be diverse.
Dilli, Christopher, Mi, William, Guzman, Miguel A.   +2 more
openaire   +2 more sources

CALR/HIF‐1α Positive Feedback Loop Drives CALR Upregulation to Promote EMT‐Mediated Bladder Cancer Progression via ROS/AKT Axis

Cancer Science, EarlyView.
This study first found that the high expression of CALR is due to a novel positive feedback loop with HIF‐1α in the tumor microenvironment: CALR stabilizes HIF‐1α protein, while HIF‐1α transcriptionally upregulates CALR expression, thereby self‐sustaining its high expression levels in BLCA.
Xintao Tian, Yue Liu, Zhiyuan Mi, Ye Liang, Zhao Zhang, Xiaocheng Ma, Huiqing Jia, Yuxuan Cao, Zhijuan Liang, Shaonan Yang, Guofeng Ma, Haitao Niu   +11 more
wiley   +1 more source